Physician profile
Michael K Smith
NPI 1477517415
$289.39
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $42.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.59 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.51 | 2019-2020 | |
| Genentech USA, INC. | $27.55 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $27.49 | 2019 | |
| Merck Sharp & Dohme LLC | $25.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.49 | 2019 | |
| Cranial Technologies, INC | $23.48 | 2019 | |
| Sobi, INC | $16.75 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.22 | 2019 | |
| Lundbeck LLC | $15.26 | 2019 | |
| Tris Pharma INC | $14.76 | 2019 | |
| Glaxosmithkline, LLC. | $12.61 | 2019 | |
| Smith+Nephew, INC. | $12.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.